Engagements of TLR7 or TLR8 agonists in lung cancer cells can induce the activation of NF-κB and upregulation of Bcl-2 expression, leading to increases in cell survival and resistance to apoptosis [47]. The gene discussed is NFKB1; the disease is lung cancer.